Zhihong Li

USPTO Granted Patents = 16 (Patent Applications = 13)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 9.0

ph-index = 7

Forward Citations = 498(Granted Patents)

Location History:

Burlingame, CA (US) (2006)
Millbrae, CA (US) (2013 - 2022)

Company Filing History:

Corvus Pharmaceuticals, Inc.

patents

Years Active: 2006-2022

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

2. 11254686 - Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor (2022-02-22),

3. 10836779 - Compounds that inhibit MCL-1 protein (2020-11-17),

4. 10100063 - Compounds that inhibit Mcl-1 protein (2018-10-16),

5. 9593129 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2017-03-14),

6. 9376425 - Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer (2016-06-28),

7. 9359355 - Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 (2016-06-07),

8. 9296736 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2016-03-29),

9. 8980903 - Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors (2015-03-17),

10. 8841312 - Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors (2014-09-23),

11. 8623885 - Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 (2014-01-07),

12. 8569341 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2013-10-29),

13. 8389533 - Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors (2013-03-05),

14. 7129261 - Cytotoxic agents (2006-10-31),

15. 7087600 - Peptidyl prodrugs and linkers and stabilizers useful therefor (2006-08-08),

Title: Innovations in Cytotoxic Agents by Inventor Zhihong Li

Introduction

Zhihong Li, an accomplished inventor based in Burlingame, CA, has significantly contributed to the field of medicinal chemistry with a focus on cytotoxic agents. His innovative work has led to the development of novel compounds that hold promise for advancing therapeutic strategies against various malignancies.

Latest Patents

Li holds three patents, with his latest inventions centered around analogues of duocarmycins, which are identified as potent cytotoxins. One of his groundbreaking patents focuses on providing peptidyl and disulfide linkers that are cleaved in vivo, enhancing the efficacy of these cytotoxins. Additionally, this invention presents prodrugs and conjugates of duocarmycin analogues with novel linker arms designed for improved therapeutic applications.

Career Highlights

Zhihong Li is currently associated with Medarex Inc., where his work integrates cutting-edge research and development in therapeutic agents. His expertise in the creation of potent cytotoxic compounds underscores his role as a key contributor to the fight against cancer.

Collaborations

Throughout his career, Li has worked alongside esteemed colleagues, including Howard P Ng and Oliver L Saunders. Their collaboration fosters an environment of innovation and shared knowledge, essential for the advancement of cutting-edge medicinal solutions.

Conclusion

As an inventive force in the realm of cytotoxic agents, Zhihong Li exemplifies the impact that innovative minds can have on healthcare and therapeutic developments. His work continues to push the boundaries of medical science, paving the way for more effective treatments for cancer and offering hope for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.